United States Federal Circuit
Impax Lab. Inc. v. Lannett Holdings Inc, 17-2020
Affirmed the ruling that certain patent claims for pharmaceutical formulations, intranasal administration devices or aqueous solutions of zolmitripatan are not valid. The court found that defendant failed to prove that the claims at issue would have been obvious over the prior art.
Appellate Information
- Published 2018/06/28
Judges
- Lourie
Court
- United States Federal Circuit